{"id":103325,"date":"2025-04-09T09:11:47","date_gmt":"2025-04-09T07:11:47","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/?p=103325"},"modified":"2025-10-13T15:11:33","modified_gmt":"2025-10-13T13:11:33","slug":"accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/","title":{"rendered":"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson"},"content":{"rendered":"<p><strong>La biotecnol\u00f3gica <a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/accure-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Accure Therapeutics<\/a>, centrada en el desarrollo de tratamientos innovadores para enfermedades del sistema nervioso central, ha anunciado la obtenci\u00f3n de 1,48 millones de euros en subvenciones otorgadas por la Fundaci\u00f3n Michael J. Fox (MJFF) y el Fondo Nacional de Investigaci\u00f3n de Luxemburgo (FNR). Esta financiaci\u00f3n permitir\u00e1 impulsar el desarrollo de su candidato a f\u00e1rmaco ACT-02 para la enfermedad de Parkinson. Con sede en el Parque Cient\u00edfico de Barcelona, la compa\u00f1\u00eda prev\u00e9 alcanzar la fase cl\u00ednica a finales de 2026.<\/strong><\/p>\n<p>La financiaci\u00f3n impulsar\u00e1 dos programas de desarrollo precl\u00ednico para su f\u00e1rmaco pionero, ACT-02, un compuesto innovador con potencial para modificar la enfermedad. ACT-02 act\u00faa como inhibidor de la prolil-endopeptidasa, una diana terap\u00e9utica prometedora que hasta ahora ha sido escasamente explorada. Actualmente, el programa se encuentra en una fase precl\u00ednica avanzada, respaldado por resultados positivos de eficacia en modelos in vivo de la enfermedad de Parkinson, as\u00ed como por datos favorables de seguridad y toxicolog\u00eda bajo normativa GLP (Buenas Pr\u00e1cticas de Laboratorio).<\/p>\n<p>Accure Therapeutics ha recibido una subvenci\u00f3n de 1\u202fM\u20ac de la Fundaci\u00f3n Michael J. Fox que ser\u00e1 destinada a completar las actividades precl\u00ednicas necesarias para completar los estudios de investigaci\u00f3n de nuevos f\u00e1rmacos (IND), con vistas a presentar una solicitud para el acceso al ensayo cl\u00ednico de fase I en 2026. Este proyecto se est\u00e1 llevando a cabo en colaboraci\u00f3n con el Instituto de Farmacolog\u00eda, Toxicolog\u00eda y Farmacia de la Stiftung Tier\u00e4rztliche Hochschule Hannover.<\/p>\n<p>Por su parte, el programa FNR BRIDGES, gestionado por el Fondo Nacional de Investigaci\u00f3n de Luxemburgo (FNR), ha ofrecido su apoyo financiero con una subvenci\u00f3n de 480.000\u202f\u20ac con el objetivo de evaluar la eficacia del f\u00e1rmaco candidato ACT-02 en modelos altamente traslacionales de la enfermedad de Parkinson con c\u00e9lulas madre pluripotentes inducidas (iPSC) derivadas de pacientes, para mejorar la selecci\u00f3n y estratificaci\u00f3n de pacientes para futuras estrategias de medicina de precisi\u00f3n.<\/p>\n<p>\u201cAgradecemos a la Fundaci\u00f3n Michael J. Fox y el Fondo Nacional de Investigaci\u00f3n de Luxemburgo su apoyo financiero a nuestro activo ACT-02 como una terapia potencial para las personas con Parkinson. Estas dos subvenciones son pasos significativos hacia adelante para nosotros y nuestros socios acad\u00e9micos en el desarrollo de nuestro primer candidato a f\u00e1rmaco en su clase, ACT- 02, para la enfermedad de Parkinson\u00bb, explica<strong> Laurent Nguyen<\/strong>, cofundador y CEO de Accure Therapeutics. \u00abSiguiendo las huellas de ACT-01, nuestro primer programa neuroprotector que recientemente logr\u00f3 resultados positivos en la fase II de ensayos cl\u00ednicos en neuro-oftalmolog\u00eda, nuestro objetivo con ACT-02 es desarrollar un medicamento que cambie las reglas del juego\u00bb, a\u00f1ade Nguyen.<\/p>\n<p><strong>\u00bb\u00a0<a href=\"https:\/\/accure.health\/accure-therapeutics-awarded-a-total-of-1-6m-in-grants-from-the-michael-j-fox-foundation-and-fonds-national-de-recherche-de-luxembourg-to-bring-first-in-class-drug-for-parkinsons-disease-t\/\" target=\"_blank\" rel=\"noopener\">M\u00e1s informaci\u00f3n [+]<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La biotecnol\u00f3gica Accure Therapeutics, centrada en el desarrollo de tratamientos innovadores para enfermedades del sistema nervioso central, ha anunciado la obtenci\u00f3n de 1,48 millones de euros en subvenciones otorgadas por&#8230;<\/p>\n","protected":false},"author":1,"featured_media":103365,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[356],"tags":[295],"class_list":["post-103325","post","type-post","status-publish","format-standard","has-post-thumbnail","category-empresas","tag-accure-therapeutics"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"La financiaci\u00f3n impulsar\u00e1 dos programas de desarrollo precl\u00ednico para su f\u00e1rmaco pionero, ACT-02 con potencial para modificar la enfermedad.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La financiaci\u00f3n impulsar\u00e1 dos programas de desarrollo precl\u00ednico para su f\u00e1rmaco pionero, ACT-02 con potencial para modificar la enfermedad.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T07:11:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T13:11:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson\",\"datePublished\":\"2025-04-09T07:11:47+00:00\",\"dateModified\":\"2025-10-13T13:11:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/\"},\"wordCount\":476,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-3.png\",\"keywords\":[\"Accure Therapeutics\"],\"articleSection\":[\"EMPRESAS\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/\",\"name\":\"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-3.png\",\"datePublished\":\"2025-04-09T07:11:47+00:00\",\"dateModified\":\"2025-10-13T13:11:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"description\":\"La financiaci\u00f3n impulsar\u00e1 dos programas de desarrollo precl\u00ednico para su f\u00e1rmaco pionero, ACT-02 con potencial para modificar la enfermedad.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-3.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-3.png\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson - Parc Cient\u00edfic de Barcelona","description":"La financiaci\u00f3n impulsar\u00e1 dos programas de desarrollo precl\u00ednico para su f\u00e1rmaco pionero, ACT-02 con potencial para modificar la enfermedad.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/","og_locale":"es_ES","og_type":"article","og_title":"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson - Parc Cient\u00edfic de Barcelona","og_description":"La financiaci\u00f3n impulsar\u00e1 dos programas de desarrollo precl\u00ednico para su f\u00e1rmaco pionero, ACT-02 con potencial para modificar la enfermedad.","og_url":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2025-04-09T07:11:47+00:00","article_modified_time":"2025-10-13T13:11:33+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","type":"image\/png"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson","datePublished":"2025-04-09T07:11:47+00:00","dateModified":"2025-10-13T13:11:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/"},"wordCount":476,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","keywords":["Accure Therapeutics"],"articleSection":["EMPRESAS"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/","url":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/","name":"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","datePublished":"2025-04-09T07:11:47+00:00","dateModified":"2025-10-13T13:11:33+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"description":"La financiaci\u00f3n impulsar\u00e1 dos programas de desarrollo precl\u00ednico para su f\u00e1rmaco pionero, ACT-02 con potencial para modificar la enfermedad.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/accure-therapeutics-consigue-15-me-en-subvenciones-para-acelerar-el-desarrollo-de-su-farmaco-act-02-contra-el-parkinson\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Accure Therapeutics consigue 1,5 M\u20ac en subvenciones para acelerar el desarrollo de su f\u00e1rmaco ACT-02 contra el Parkinson"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/103325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=103325"}],"version-history":[{"count":3,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/103325\/revisions"}],"predecessor-version":[{"id":103464,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/103325\/revisions\/103464"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/103365"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=103325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=103325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=103325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}